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Abstract
Background Despite the findings of several randomized
clinical studies, the role of gentamicin collagen implant
(GCI) in rectal cancer surgery is unclear. Local pelvic
application of GCI following preoperative radiotherapy
and total mesorectal excision (TME) was evaluated to
determine the risk of surgical site infections (SSI).
Methods In this single-center trial, 176 patients with
rectal cancer after preoperative, short-term radiotherapy
(5 9 5 Gy) were randomized either to the study group in
which GCI was used or in the control group without GCI.
Prior to surgery and intraoperatively five patients were
excluded from the study. The remaining 171 patients were
analyzed; 86 were in the study group and 85 in the control
group.
Results There were no statistically significant differences
in the overall rate of early postoperative complications
between the study and control group: 25.6 and 34.1 %
respectively; p = 0.245, relative risk (RR) 0.750 [95 %
confidence interval (CI) 0.471–1.195]. The reoperation rate
was similar in both groups: 12.8 versus 9.4 %; p = 0.628;
RR 1.359; (95 % CI 0.575–3.212). The total rate of SSI
and organ space SSI were 22.2 and 15.8 % without dif-
ferences between the study and control group. In patients
without anastomotic leakage, the risk of organ space SSI
was significantly reduced in patients who received GCI: 2.6
versus 13.0 %; p = 0.018.
Conclusions Application of GCI in the pelvic cavity after
short-term preoperative radiotherapy and TME may reduce
the risk of organ space SSI but only in the absence of
anastomotic leakage.
Keywords Surgical site infection  Gentamicin collagen
implant  Rectal cancer  TME
Introduction
Experience from several randomized studies has suggested
that local application of gentamicin collagen implant (GCI)
may reduce the rate of surgical site infection (SSI) [1–5],
whereas other multicenter, randomized studies have shown
GCI had no effect [6, 7]. Only four studies focused on
patients with rectal cancer [2–4, 6] and only in one did all
patients receive preoperative short-term radiotherapy [4].
In most of these studies, the GCI was inserted into the
wound above the abdominal fascia or into the sacral wound
after abdominoperineal resection (APR) and complete
closure of the pelvic peritoneal floor at the level with the
remnants of the levators. Following total mesorectal
A. Rutkowski (&)  L. Zaja˛c  M. Bednarczyk  T. Olesin´ski 
M. Szpakowski  P. Saramak
Department of Oncological Gastroenterology, Maria




Department of Radiotherapy, Maria Sklodowska-Curie
Memorial Cancer Centre, Warsaw, Poland
A. Byszek
Department of Clinical Trials, Maria Sklodowska-Curie
Memorial Cancer Centre, Warsaw, Poland
J. Oledzki
Department of General, Vascular and Transplant Surgery,
Medical University of Warsaw, Warsaw, Poland
M. Chwalinski
Department of Surgery, St. Elizabeth Hospital, Warsaw, Poland
123
Tech Coloproctol (2014) 18:921–928
DOI 10.1007/s10151-014-1193-1
excision (TME), an empty cavity and specific type of
surgical wound appear in the pelvic area. Moreover, the
risk of infective complications in patients who undergo
preoperative radiotherapy is higher than in patients who
have surgery alone [8]. In one randomized study conducted
by our group on rectal cancer patients, the GCI was
inserted into the pelvic cavity after TME but only 50.6 %
of patients received preoperative radiotherapy [3]. There
were fewer early postoperative complications in the GCI
group (20.7 vs. 37.5 %; p = 0.044). Analysis of this study
showed that patients in the study group undergoing radical
resection had significantly better overall survival (OS) and
disease-free survival (DFS) than those allocated to the
control group, mainly due to reduction of the incidence of
distant metastases. The reasons for this remain unknown. In
another randomized study evaluating the effect of GCI in
the prevention of perineal wound complications after APR,
there were no statistically significant differences seen in
rates of cancer recurrence between the treatment and
control groups [6]. Due to conflicting results of these
studies, it was decided to initiate a confirmatory random-
ized trial. The main objective of the study was the evalu-
ation of the rate of local recurrence and distant recurrence
in patients after R0 resection. The oncological outcomes
will published after the completion of follow-up. The
second objective was the assessment of risk of SSI
(superficial, deep and organ space) and total risk of post-
operative complications. The current evaluation presented
an impact of the GCI on the risk of surgical site infections.
Materials and methods
Study design
The local ethics committee at the Centre of Oncology in
Warsaw approved the study. Participation in the study was
open to patients with resectable rectal cancer who were
eligible for preoperative short-term radiotherapy and TME.
Preoperative inclusion criteria were pathology confirmed
adenocarcinoma of the rectum located up to 12 cm from
the anal verge, age C18 years, World Health Organization
(WHO) performance score 0–1, no distant metastases,
cancer stage cT3-4, N0-2, or cT2 N1-2, preoperative short-
term radiotherapy with 5 9 5 Gy, and adequate results of
blood count: leukocytes C3.5 9 109/L, neutrophils/granu-
locytes C1.5 9 109/L and hemoglobin C9.0 g/dL. All
patients signed written informed consent. The exclusion
criteria were presence of distant metastases, other primary
cancer, allergy to gentamicin or collagen, pregnancy and
concomitant disorders such as ulcerative colitis or Crohn’s
disease.
Gentamicin collagen implant (GCI)
The gentamicin collagen implant (Garamycin Innocoll,
Athlone, Co., Westmeath, Ireland) contained 130 mg of
gentamicin. The maximal concentration of gentamicin in
serum after application of one GCI estimated to be about
2 lg/mL. During the first 12 h after surgery, the level of
gentamicin in the drainage exudates is approximately
80–700 times higher than in the serum [3, 9]. In addition,
GCI is highly water-soluble and even short periods of
immersion in saline before implantation may causes large
loss of gentamicin content [10].
Randomization
The patients were randomized to either the study group in
which GCI was used or to the control group in which
patients underwent operation without adjunctive use of
GCI. Randomization was carried out after radiotherapy and
before surgery by telephone to the independent trial office.
Balanced randomization lists were used. No stratification
was made.
Preoperative irradiation
In all patients, a total dose of 25 Gy in five fractions over
5 days was given. Three dimensional planning was used.
Patients were irradiated using 15 MV photon beams. The
target volume included the rectum, the mesorectum, the
lymph nodes along the iliac internal vessels, the presacral
nodes and the nodes at the obturator foramens. The interval
between the end of radiotherapy and surgery could not be
longer than 6 days but in patients for whom there were
contraindications to surgery soon after the radiotherapy
completion, it was allowed to extend the interval to
6–8 weeks.
Surgical treatment
Prior to surgery, patients underwent one day of dietary
restrictions and bowel preparation. All patients routinely
received antibiotic prophylaxis consisting of intravenous
injections of metronidazole 500 mg and cefuroxime
1,500 mg three times a day. The first dose was given
during premedication in the operating theater. The prefer-
able duration of the prophylaxis was 24 h with an accept-
able 3-day option. Low molecular weight heparin was used
as thrombosis prophylaxis.
Tumors located in the lower and middle part of the
rectum were resected by the use of the TME technique.
Tumors located from 10 to 12 cm from the anal verge were
removed by subtotal mesorectal excision, but in these
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cases, the mesorectum was transected at least 3 cm below
the level of the lower tumor border. A lateral pelvic lym-
phadenectomy was not performed. At the early stage of the
operation, high ligation of the inferior mesenteric artery or
superior rectal artery was carried out. In most cases of
anterior resection, the double stapler technique and end-to-
end anastomosis were used. Colonic pouches or protective
diverting stoma creation was left to the discretion of
attending surgeon. Low anterior resection was defined as
resection with anastomosis up to 6 cm from the anal verge.
All patients had pelvic cavity drainage for the first 48 h
after the operation. For very low lesions, the extralevator
type of APR was carried out. In patients who were ran-
domly assigned to receive GCI 2 implants were inserted in
the space created after mesorectal resection. The implants
were not wetted before implantation, and the abdominal
cavity was not washed after GCI application. In the case of
APR, the implants were inserted via the perineal wound
before complete closure of the pelvic peritoneal floor.
Follow-up evaluations, endpoints and definitions
All postoperative complications within 90 days after
operation were recorded. Data concerning complications
after discharge were collected during routine control visits
30 and 90 days after surgery. No data were gathered on late
surgical and postradiation complications. The endpoint for
the current analysis was the total rate of SSI which inclu-
ded superficial incisional infections and organ space
infections according to the Centers for Disease Control
(CDC) definitions [11] and other postoperative complica-
tions. Intra-abdominal infections were defined according to
5th Edition (2010) of Scottish Surveillance of Healthcare
Associated Infection Programme (SSHAIP) Health Pro-
tection Scotland (HPS). In accordance with this, organ
space SSI was diagnosed if one of the following criteria
were met:
• Patient has organisms cultured from purulent material
from intra-abdominal space obtained during a surgical
operation or from drainage or needle aspiration and
• Patient has abscess or other evidence of intra-abdom-
inal infection seen during a surgical operation or
histopathologic examination or patient has at least
two of the following signs, fever ([38 C), nausea,
vomiting, abdominal pain and radiographic evidence of
infection, e.g., abnormal findings on ultrasound, com-
puted tomography (CT) scan, magnetic resonance
imaging (MRI) or abdominal X-ray.
Categories of complications were assessed using the
Dindo classification [12]. In this study, organ space SSIs
were classified as intra-abdominal or intrapelvic abscess
and/or peritonitis with or without clinically diagnosed
anastomotic leakage. The diagnosis of anastomotic leakage
was based on digital rectal examination or observation of
fecal material in the drain and confirmed radiologically in
CT pelvic scan or by laparotomy. Intra-abdominal pelvic
abscess near the anastomotic leakage site was considered a
result of the leakage only when leakage was confirmed.
Such a complication was classified as organ space SSI
caused by anastomotic leakage. If anastomosis dehiscence
was not confirmed, intra-abdominal abscess, peritonitis or
purulent drainage from the pelvis were classified as organ
space SSI without anastomotic leakage. This category of
complications also included patients with pelvic pain and
the fever above 38 C lasting more than 48 h with sus-
pected inflammatory infiltration of soft tissue in the pelvis
on CT examination but without evidence of anastomotic
leakage or abscess.
Statistical analysis
All data were collected in case report forms. Standard
methods of descriptive statistics were employed for
demographic data. The calculation of the sample size was
based on the primary endpoint of the study which was local
recurrence and distant recurrence in patients after R0
resection. To this end, there should have been 176 ran-
domized patients. As far as the study power for detecting
differences in perineal wound complication rate, assuming
there is a 30 % postoperative complication rate after pre-
operative radiotherapy and radical resection of rectal can-
cer, to detect 50 % reduction of complications at the
significance level of 95 % and power of 80 % between two
treatment-assigned groups, more than 200 patients would
be needed. The analyses were carried out according to the
intention-to-treat principle. Differences in proportions were
assessed using the Chi-square test or Fisher’s exact test.
Continuous variables were compared using the Mann–
Whitney U test. For all tests, the statistical significance was
accepted at a = 0.05. The data were analyzed with SPSS
14 for Windows (SPSS, Chicago, IL, USA).
Results
From January 2008 to September 2011, out of 193 patients
with rectal cancer who had undergone preoperative short-
term radiotherapy, 177 (91.7 %) patients met all inclusion
criteria. One patient did not agree to participate in the
study. Altogether, 176 patients were randomized. However,
immediately prior to surgery, two patients withdrew con-
sent. Intraoperatively, another three patients were exclu-
ded, leaving 171 patients who were analyzed; 86 in the
GCI group and 85 in the control group (Fig. 1).
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Patient characteristics
Patient characteristics were well balanced between the
treatment assignment groups (Table 1). In total, 115 men
(67.3 %) and 56 women (32.7 %) with a mean age of
63 years were analyzed. Median distance between the anal
verge and lower tumor border was 5.3 cm. Surgery within
one week after completion of short-term radiotherapy was
performed in 145 patients (85 %). The remaining 26
patients (15 %) were operated on 6–8 weeks after radio-
therapy. One hundred and thirty-three patients (77 %)
underwent TME. In the remaining 40 patients (23 %) with
high tumor, subtotal mesorectal excision was performed. A
total of 50 (29 %) and 103 (60 %) patients underwent APR
and anterior resection, respectively. A protective stoma
was created in total of 18 % patients undergoing anterior
resection: 15 % in the study group and 22 % in the control
group (p = 0.476). The Hartmann procedure was per-
formed in the remaining 18 patients (11 %). Median
duration of surgical procedure was 145 min. In 151
patients (88 %), a 3-day course of antibiotic prophylaxis
was used (78 in GCI group and 73 in control group).
Postoperative complications
Postoperative complications occurred in total of 51
(29.8 %) patients; 22 of 86 patients (25.6 %) in the GCI
group and 29 of 85 (34.1 %) in the control group;
GCI- gentamicin collagen implant  
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Fig. 1 Profile of the study
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p = 0.245, relative risk (RR) 0.750; (95 % CI
0.471–1.195). There were no 30-day postoperative deaths.
Grade 3 or 4 complications according to the Dindo clas-
sification were observed in 20 patients (11.7 %): 11 of 86
patients (12.8 %) in the GCI group and 9 of 85 (10.6 %) in
the control group; p = 0.813; RR 1.208; (95 % CI
0.528–2.766). In the remaining 31 patients, grade 1 or 2
complications occurred. Intraoperative complications
occurred in 16 patients (6 patients in the study group and
10 in the control group). Application of GCI in such cases
did not influence postoperative complications (p = 0.234).
When surgery time exceeded C180 min, the rate of com-
plications was 30.4 % in the GCI group and 50 % in the
control group; p = 0.334; RR 0.609; (95 % CI
0.281–1.317). The reoperation rate was similar in both
groups: 11 of 86 (12.8 %) versus 8 of 85 (9.4 %) respec-
tively, p = 0.628; RR 1.359; (95 % CI 0.575–3.212). The
total rate of clinical anastomotic leakage was 13.6 %; 17 %
in the GCI group and 10 % in the control group,
p = 0.392; RR 1.698; (95 % CI 0.611–4.722). A protective
stoma had no effect on the observed differences in the rate
of anastomotic leak between both groups. Reoperation was
necessary in 11 patients (78.6 %) with anastomotic dehis-
cence; eight of nine (89 %) in the GCI group and three of
five (60 %) in the control group, p = 0.505; RR 0.675;
(95 % CI 0.318–1.432). In patients who underwent APR,
abdominal and perineal wound infections occurred in 4 and
2 % respectively. Application of GCI in the pelvic cavity
did not reduce the risk of infections.
Surgical site infections (SSI)
The overall rate of SSI was 22.2 % (38 of 171 patients).
Superficial or deep wound infection was diagnosed in 12
patients (7 %) and organ space SSI in 27 (15.8 %). Seven
patients had both superficial and organ space SSI. If
anastomotic leakage occurred, application of GCI did not
affect the risk of organ space SSI. However, if there was no
leakage, the risk of organ space SSI was significantly
reduced in patients who received GCI: 2.6 % (95 %CI
0–6.2) versus 13.8 % (95 % CI 6.2–21.4); p = 0.018
(Table 2). Unplanned analysis of the subgroup of patients
without anastomotic leakage showed that the type of sur-
gery, TME technique and operative time had no impact on
the risk of organ space SSI in both groups (Table 3). The
median time of hospitalization was the same in both groups
(median 8 days).
Discussion
Earlier studies focused on the assessment of the risk of
incisional and deep SSI depending on GCI application [1,
2, 4–7]. In most of these studies, the GCI was inserted into
the wound above the abdominal fascia or into the sacral
wound after APR. What is more, only four of the studies
focused on patients with rectal cancer—Table 4 [2–4, 6].
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In addition, the studies concerning the colorectal surgery
occasionally show contradictory results. The surprising
result of a randomized multicenter trial from the USA
reveals a significantly higher rate of SSI in the GCI group
[7]. The important bias of this study was the fact that the
implants were soaked in saline prior to implantation.
Lovering et al. [10] showed that after relatively short
periods (2–60 s) of immersion of GCI in saline, losses of
gentamicin were observed (from 6.7 to 40.5 %). This could
have an impact on the efficacy of GCI. On the other hand, a
review of clinical trials presented by de Bruin demonstrates
that application of GCI can reduce the risk of SSI [13].
Brehant et al. [14] presented similar conclusions on the
basis of a prospective analysis of 606 patients after colo-
rectal surgery. The results of our previous study show
positive effects of GCI, mainly in patients with surgery
lasting longer than 180 min (19.2 vs. 40.8 %; p = 0.031)
and in patients with intraoperative complications (10 vs.
57.9 %; p = 0.001) [3]. Contrary to other studies that
focused on the assessment of the risk of incisional and deep
SSI depending on GCI application, the current analysis also
applies to organ space SSI. It is connected with the site of
GCI application—the pelvic cavity. The results indicate
that the application of GCI at the site of removed
mesorectum reduces the risk of organ space SSI but only
when the anastomotic integrity is maintained. Although in
the current trial, GCI patients experienced a lower number
of postoperative complications, the difference is not sta-
tistically significant and operating time did not influence
the complication risk.
The total rate of SSI and organ space SSI was 22.8 and
16 %, respectively. These results are similar to those
reported by other authors [15–17]. The overall incidence of
organ space SSI with and without anastomotic leakage was
9.3 and 8 %, respectively. Other authors have shown lower
rates of organ space SSI with and without anastomotic
leakage (2 and 0.8 %, respectively), but these results are
for colon and rectal surgery [18]. There are many known
risk factors for total and/or organ space SSI after elective
colorectal surgery: tumor situated below peritoneal reflec-
tion (11 cm from the anal verge), types of operation (low
anterior resection and Hartmann procedure), blood trans-
fusion, poor general condition [American Society of
Anesthesiologists (ASA) score 2 or 3], male gender, use of
drainage, surgeon experience and stoma creation [15–19].
Most of these are also risk factors for anastomotic leakage
[20–23]. Despite the fact that the difference in the rates of
anastomotic leakage was not statistically significant, the
Table 2 Surgical site infection
No. of SSI/total no. of patients (%) p value RR 95 % CI
GCI group Control group
Superficial and/or deep incisional SSI 5/86 (5.8) 7/85 (8.2) 0.566 0.706 0.233–2.138
Organ space SSI 11/86 (12.8) 16/85 (18.8) 0.302 0.680 0.335–1.378
With anastomotic leakagea 9/53 (17) 5/50 (10) 0.389 1.698 0.602–4.722
Without anastomotic leakageb 2/77 (2.6) 11/80 (13.8) 0.018 0.189 0.043–0.825
Total SSI 16/86 (18.6) 22/85 (25.9) 0.275 0.719 0.407–1.271
GCI gentamicin collagen implant, SSI surgical site infection, RR relative risk, CI confidence interval
a Anterior resection only
b Patients with anastomotic leakage excluded
Table 3 Organ space surgical site infection without anastomotic leakage





Abdominoperineal resection 2/26 (7.7) 3/24 (12.5) 0.661 0.615 0.112–3.372
Low anterior resection 0/28 (–) 3/33 (9.4) 0.243 0.168 0.009–3.110
Anterior resection 0/16 (–) 0/12 (–) (–) (–) (–)
Hartmann procedure 0/7 (–) 5/11 (45.6) 0.101 0.136 0.009–2.140
Total mesorectal excision (TME) 2/58 (3.4) 8/64 (12.5) 0.099 0.276 0.061–1.247
Intraoperative complications 0/6 (–) 3/10 (30.0) 0.250 0.225 0.014–3.720
Surgical procedure duration C180 min 1/20 (5.0) 5/18 (27.8) 0.083 0.180 0.023–1.399
GCI gentamicin collagen implant, TME total mesorectal excision, RR relative risk, CI confidence interval
a Patients with anastomotic leakage excluded
926 Tech Coloproctol (2014) 18:921–928
123
high rate of clinical anastomotic leakage in the GCI group
(18 %) may seem disturbing. Moreover, eight of nine
(89 %) patients with anastomotic leakage who received
GCI required reoperation, while in the control group,
reoperation was necessary in only in two of four (50 %)
patients with leakage. No connection between GCI appli-
cation and anastomotic leakage has been shown in the lit-
erature [14, 24, 25]. There is also no data on the influence
of high gentamicin concentrations and collagen upon the
healing process of bowel anastomoses. There has been only
one randomized study in which GCI was inserted around
the colorectal anastomosis, but GCI had no effect on the
risk of the leakage [3]. Although there is uncertainty as to
whether organ space SSI in the form of a pelvic abscess at
the site of the anastomosis is equivalent to leakage, the
likelihood is that this is the case [19, 26]. Therefore, the
distinction between organ space SSI with and without
anastomotic leakage is justified. The results of the study
showed that the risk of organ space SSI was significantly
lower in those patients in whom GCI was used, but only
when anastomotic leakage did not occur. This suggests that
anastomotic leakage is such a significant risk factor for
organ space SSI that the application of GCI does not pre-
vent it. The low total rate of perineal wound infections
(only 2 %) is surprising, while other authors have reported
a higher percentage ([10 %) [2, 4, 6]. The reason for this
phenomenon is unknown.
The current study has certain limitations. First, it should
be stressed that assessment of postoperative complications
was a secondary aim of the study, and therefore, the study
lacks adequate power. Secondly, fewer patients received
GCI due to protocol deviation. Thirdly, organ space SSI was
not always confirmed by bacteriologic investigation. Bac-
teriological swabs were taken routinely during relaparotomy
and from the wound if clinical symptoms of infection were
present. The diagnosis of organ space SSI in the pelvic area
without the presence of abscess and anastomotic leakage was
based on clinical symptoms (pain and fever) and CT imagery
(inflammatory infiltration of soft tissue of the pelvis) alone.
Unfortunately, inflammatory lesions of soft tissue in the
immediate postoperative period are virtually indistinguish-
able from early postoperative lesions not associated with
infection. Therefore, the interpretation of CT imagery in
connection with clinical symptoms depended in such cases
entirely upon the surgeon and radiologist.
Conclusions
Despite important limitations, the results of this study
indicate that implantation of GCI in the pelvic cavity fol-
lowing short-term preoperative radiotherapy and TME for
rectal cancer can reduce organ space SSI but only in the
absence of anastomotic leakage.
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